Suresh Katti

Suresh Katti, Ph.D., was most recently Director of Protein Sciences at Alexion Pharmaceuticals where he contributed towards advancing three antibodies and an enzyme replacement molecule into clinical development.

Prior to that he served as Director of Drug Discovery and Design at Optherion Inc. where he helped establish a biologics discovery research group. Previously, he held several positions of increasing responsibilities at Bayer Pharmaceuticals and contributed to the discovery and development of several small molecule therapeutics in oncology and osteoporosis indications.

Dr. Katti received his Ph.D. from Indian Institute of Science and then completed his postdoctoral training at Yale University in the field of structural biology.